Aquestive Therapeutics (NASDAQ:AQST) Given “Buy” Rating at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 114.59% from the stock’s previous close.

A number of other research analysts also recently commented on the company. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Price Performance

AQST stock opened at $4.66 on Monday. The company has a 50 day moving average of $4.18 and a two-hundred day moving average of $4.12. The company has a market cap of $584.89 million, a price-to-earnings ratio of -7.17 and a beta of 1.49. Aquestive Therapeutics has a 12-month low of $2.93 and a 12-month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. On average, research analysts anticipate that Aquestive Therapeutics will post -0.5 EPS for the current year.

Insider Activity at Aquestive Therapeutics

In other news, Director Julie Krop sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director owned 25,000 shares in the company, valued at approximately $125,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of large investors have recently bought and sold shares of AQST. NewEdge Advisors LLC bought a new position in Aquestive Therapeutics during the third quarter valued at about $28,000. BNP Paribas Financial Markets boosted its stake in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter valued at about $33,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Aquestive Therapeutics during the 1st quarter valued at about $42,000. Finally, ADAR1 Capital Management LLC raised its stake in shares of Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.